The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: WVE), whose shares ...

that is exactly where the agency's scientists attached wave sensors late Wednesday between Venice and Panama City. The USGS ...

Eager to not meet a similar fate, the National Academy of Sciences has called for planetary defense to be a national priority ...

Clinical-stage biotechnology company Wave Life Sciences (NASDAQ:WVE) priced an underwritten public offering of ~23.13M of its ordinary shares at a price to the public of $8.00 per ordinary share.

Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to ...

WAVE LIFE SCIENCES - PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 23.12 MILLION AT A PRICE TO PUBLIC OF $8.00 PER ORDINARY SHARE Source text for Eikon: Further company coverage: ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed has given his Buy ...

The company’s stock rose by 53.37% from $5.34 at close on 23 September to $8.19 at close yesterday (24 September).

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Wave Life Sciences (WVE – Research Report). The ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.